Facebook Twitter LinkedIn YouTube Instagram

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Namilumab

Status:

Phase 2

Condition:

Sarcoidosis ILD

Intervention Type:

Subcutaneous (SC) Injection

Funder Type:

Industry

Drug Details

Namilumab is an investigational, novel fully human monoclonal antibody administered once a month as a subcutaneous injection. Namilumab is a potent GM-CSF inhibitor.

Study Purpose

This is a randomized, double-blind, placebo-controlled study with an open-label extension (OLE).

Find a Clinical Trial